| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy | 14 | 2023 | 144 | 1.490 |
Why?
|
| Antineoplastic Agents | 6 | 2026 | 1019 | 1.400 |
Why?
|
| Neoplasms | 9 | 2025 | 1377 | 1.330 |
Why?
|
| Multiple Myeloma | 7 | 2014 | 48 | 1.280 |
Why?
|
| Amyloidosis | 2 | 2025 | 37 | 1.070 |
Why?
|
| Antigens, Neoplasm | 11 | 2015 | 90 | 1.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2026 | 2 | 0.970 |
Why?
|
| Ulcer | 1 | 2026 | 6 | 0.970 |
Why?
|
| Eosinophils | 1 | 2026 | 24 | 0.960 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2026 | 21 | 0.940 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2025 | 5 | 0.920 |
Why?
|
| Heart Failure | 2 | 2025 | 302 | 0.860 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 65 | 0.850 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 38 | 0.750 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2023 | 226 | 0.750 |
Why?
|
| Humans | 58 | 2026 | 43102 | 0.690 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 2 | 0.680 |
Why?
|
| Hand Dermatoses | 1 | 2021 | 2 | 0.680 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 8 | 0.680 |
Why?
|
| Genistein | 2 | 2011 | 45 | 0.660 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 40 | 0.660 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 291 | 0.650 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 44 | 0.650 |
Why?
|
| Testis | 5 | 2012 | 207 | 0.640 |
Why?
|
| Leadership | 1 | 2021 | 86 | 0.640 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2020 | 1 | 0.640 |
Why?
|
| Papillomavirus Vaccines | 2 | 2014 | 174 | 0.640 |
Why?
|
| Myocarditis | 1 | 2020 | 24 | 0.620 |
Why?
|
| Education, Medical | 1 | 2021 | 118 | 0.610 |
Why?
|
| Papillomavirus Infections | 3 | 2025 | 376 | 0.600 |
Why?
|
| Factor VII Deficiency | 1 | 2019 | 1 | 0.600 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2019 | 1 | 0.600 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2019 | 1 | 0.600 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2019 | 2 | 0.600 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 8 | 0.590 |
Why?
|
| Trisomy | 1 | 2019 | 11 | 0.590 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 14 | 0.590 |
Why?
|
| Glioblastoma | 1 | 2019 | 74 | 0.540 |
Why?
|
| Ovarian Neoplasms | 8 | 2014 | 415 | 0.490 |
Why?
|
| Public Health | 1 | 2021 | 424 | 0.490 |
Why?
|
| Male | 25 | 2026 | 23409 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 968 | 0.450 |
Why?
|
| Papillomaviridae | 2 | 2025 | 142 | 0.440 |
Why?
|
| Membrane Proteins | 9 | 2015 | 561 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 367 | 0.420 |
Why?
|
| Antigens, Surface | 6 | 2015 | 52 | 0.410 |
Why?
|
| Hematologic Neoplasms | 2 | 2011 | 18 | 0.410 |
Why?
|
| Apoptosis | 3 | 2014 | 1568 | 0.400 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2024 | 13 | 0.400 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 989 | 0.400 |
Why?
|
| Prostatic Neoplasms | 3 | 2019 | 1092 | 0.380 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2015 | 28 | 0.380 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 3 | 0.370 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 238 | 0.370 |
Why?
|
| Cell Cycle | 2 | 2011 | 346 | 0.360 |
Why?
|
| Alphapapillomavirus | 1 | 2012 | 31 | 0.360 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 495 | 0.350 |
Why?
|
| Lymphoma | 1 | 2011 | 41 | 0.340 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 41 | 0.340 |
Why?
|
| Carcinoma | 1 | 2012 | 108 | 0.340 |
Why?
|
| Carrier Proteins | 5 | 2015 | 321 | 0.340 |
Why?
|
| HIV Infections | 2 | 2023 | 2586 | 0.320 |
Why?
|
| Female | 26 | 2025 | 24698 | 0.320 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 77 | 0.310 |
Why?
|
| Galectin 3 | 3 | 2014 | 30 | 0.300 |
Why?
|
| Neoplasm Proteins | 3 | 2008 | 228 | 0.300 |
Why?
|
| Dependovirus | 5 | 2014 | 18 | 0.300 |
Why?
|
| A Kinase Anchor Proteins | 3 | 2015 | 12 | 0.290 |
Why?
|
| Cancer Vaccines | 4 | 2015 | 30 | 0.280 |
Why?
|
| Cell Line, Tumor | 11 | 2015 | 2676 | 0.240 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2015 | 32 | 0.240 |
Why?
|
| Gene Rearrangement | 1 | 2026 | 17 | 0.240 |
Why?
|
| Eosinophilia | 1 | 2026 | 17 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2026 | 17 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 307 | 0.240 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2026 | 58 | 0.240 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2026 | 21 | 0.240 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2025 | 1 | 0.230 |
Why?
|
| Hypotension, Orthostatic | 1 | 2025 | 6 | 0.230 |
Why?
|
| Middle Aged | 7 | 2026 | 12222 | 0.230 |
Why?
|
| Stroke Volume | 1 | 2025 | 122 | 0.210 |
Why?
|
| Mucins | 1 | 2024 | 73 | 0.200 |
Why?
|
| Histoplasmosis | 1 | 2023 | 4 | 0.200 |
Why?
|
| Sarcoma, Kaposi | 1 | 2023 | 23 | 0.190 |
Why?
|
| Adult | 7 | 2023 | 13872 | 0.190 |
Why?
|
| Herpesvirus 8, Human | 1 | 2023 | 25 | 0.190 |
Why?
|
| Iron | 1 | 2024 | 251 | 0.190 |
Why?
|
| Coccidioidomycosis | 1 | 2023 | 54 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 23 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2015 | 18 | 0.180 |
Why?
|
| Pneumonia | 1 | 2023 | 61 | 0.180 |
Why?
|
| Animals | 18 | 2024 | 16992 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 165 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 21 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2022 | 17 | 0.180 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 11 | 0.180 |
Why?
|
| Cytomegalovirus | 2 | 2014 | 45 | 0.170 |
Why?
|
| Dendritic Cells | 4 | 2011 | 132 | 0.170 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2015 | 34 | 0.170 |
Why?
|
| Fenretinide | 1 | 2021 | 9 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 100 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 173 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2021 | 91 | 0.160 |
Why?
|
| HIV | 1 | 2021 | 100 | 0.160 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 386 | 0.160 |
Why?
|
| Alcohol Drinking | 1 | 2025 | 609 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 94 | 0.150 |
Why?
|
| Thoracic Vertebrae | 1 | 2019 | 8 | 0.150 |
Why?
|
| Kidney | 1 | 2021 | 372 | 0.150 |
Why?
|
| Fatal Outcome | 3 | 2024 | 48 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 31 | 0.150 |
Why?
|
| Nigeria | 1 | 2019 | 92 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 133 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2019 | 135 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2019 | 114 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 512 | 0.140 |
Why?
|
| Breast | 1 | 2019 | 139 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 245 | 0.130 |
Why?
|
| Aged | 4 | 2025 | 8214 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 590 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 587 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2015 | 38 | 0.110 |
Why?
|
| Immunity | 1 | 2015 | 61 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2015 | 55 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 69 | 0.110 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2014 | 5 | 0.110 |
Why?
|
| Genitalia | 1 | 2014 | 18 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 99 | 0.100 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 53 | 0.100 |
Why?
|
| Organ Specificity | 2 | 2011 | 141 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2007 | 224 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2014 | 87 | 0.100 |
Why?
|
| Calmodulin-Binding Proteins | 5 | 2015 | 11 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 131 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2011 | 1455 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2015 | 1271 | 0.100 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2012 | 21 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2012 | 23 | 0.100 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 24 | 0.090 |
Why?
|
| Thrombosis | 1 | 2012 | 81 | 0.090 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2012 | 12 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2014 | 169 | 0.090 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2011 | 8 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 209 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 526 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 21 | 0.090 |
Why?
|
| Pyrazines | 1 | 2011 | 32 | 0.090 |
Why?
|
| Immunologic Surveillance | 1 | 2011 | 10 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2012 | 81 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 150 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 277 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 186 | 0.080 |
Why?
|
| Muramidase | 1 | 2010 | 30 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 161 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2010 | 41 | 0.080 |
Why?
|
| Prostate | 1 | 2011 | 155 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 259 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 347 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 372 | 0.080 |
Why?
|
| Mice | 8 | 2014 | 6644 | 0.070 |
Why?
|
| Genes, MHC Class I | 1 | 2008 | 15 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 183 | 0.070 |
Why?
|
| Immediate-Early Proteins | 1 | 2008 | 49 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2007 | 8 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 81 | 0.070 |
Why?
|
| Young Adult | 1 | 2019 | 5080 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2008 | 154 | 0.070 |
Why?
|
| Vaccination | 1 | 2010 | 355 | 0.070 |
Why?
|
| Spermatozoa | 1 | 2009 | 214 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2008 | 184 | 0.070 |
Why?
|
| Plasmids | 1 | 2008 | 244 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 38 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2008 | 192 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 259 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2010 | 876 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 518 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 206 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 163 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2011 | 51 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2008 | 460 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 7 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2024 | 37 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 16 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2011 | 411 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 95 | 0.050 |
Why?
|
| Histoplasma | 1 | 2023 | 6 | 0.050 |
Why?
|
| Fluconazole | 1 | 2023 | 41 | 0.050 |
Why?
|
| Splenomegaly | 1 | 2002 | 6 | 0.050 |
Why?
|
| Platelet Count | 1 | 2002 | 13 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 19 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2002 | 69 | 0.050 |
Why?
|
| Pelvis | 1 | 2022 | 15 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 139 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 290 | 0.050 |
Why?
|
| Proteinuria | 1 | 2021 | 56 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2853 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 11 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2023 | 169 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 53 | 0.040 |
Why?
|
| California | 1 | 2023 | 548 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1723 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2011 | 74 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 1596 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2011 | 165 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 861 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 2 | 2010 | 60 | 0.040 |
Why?
|
| Gene Expression | 2 | 2014 | 701 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2008 | 158 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 749 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 3994 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 667 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 1028 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 652 | 0.030 |
Why?
|
| Cell Line | 2 | 2010 | 1410 | 0.030 |
Why?
|
| Sex | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 1869 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2015 | 37 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 109 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 116 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 53 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 87 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2014 | 93 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 2157 | 0.030 |
Why?
|
| Transgenes | 1 | 2014 | 65 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 296 | 0.030 |
Why?
|
| Time Factors | 2 | 2010 | 1857 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 117 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 237 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 238 | 0.020 |
Why?
|
| Protamines | 1 | 2012 | 21 | 0.020 |
Why?
|
| Aorta | 1 | 2014 | 198 | 0.020 |
Why?
|
| Albumins | 1 | 2012 | 33 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 40 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Anions | 1 | 2012 | 44 | 0.020 |
Why?
|
| Static Electricity | 1 | 2012 | 86 | 0.020 |
Why?
|
| Prodrugs | 1 | 2012 | 31 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2012 | 56 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2012 | 59 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 68 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 109 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 40 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 536 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 81 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 256 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 57 | 0.020 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2011 | 4 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2011 | 19 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1285 | 0.020 |
Why?
|
| Temperature | 1 | 2012 | 313 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2011 | 18 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 45 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 61 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2011 | 68 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 195 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 655 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 154 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 183 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 220 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2010 | 29 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 47 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 147 | 0.020 |
Why?
|
| Zona Pellucida | 1 | 2009 | 1 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Lung | 1 | 2012 | 492 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 368 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 269 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 21 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2012 | 403 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 74 | 0.020 |
Why?
|
| Sperm Tail | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 196 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1035 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 329 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 945 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 384 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 449 | 0.020 |
Why?
|
| Germ Cells | 1 | 2008 | 74 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2007 | 34 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 247 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 67 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 129 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2007 | 91 | 0.020 |
Why?
|
| Cell Separation | 1 | 2007 | 94 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1621 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 934 | 0.010 |
Why?
|
| Decision Making | 1 | 2005 | 249 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 509 | 0.010 |
Why?
|